GSK scores Priority Review for anti-BCMA option in multiple myeloma

The US Food and Drug Administration has granted Priority Review status to a submission from British drugmaker GlaxoSmithKline (LSE: GSK) for belantamab mafodotin.

The anti-BCMA candidate has previously been granted Breakthrough Therapy designation, and would be the first treatment of its kind to be approved for marketing.

GSK wants to market the treatment for people with relapsed or refractory multiple myeloma whose prior therapy included an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody.